Novartis acquires local cardiovascular drugmaker Anthos for $925 million
Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...
Novartis buying US biotech company
Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.
Novartis buying US biotech firm
Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.